Welcome to our dedicated page for Baird Medical SEC filings (Ticker: BDMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Baird Medical Investment Holdings Ltd. filings document foreign-issuer current reports for a microwave ablation medical device company. The disclosed records include Form 6-K reporting on auditor changes, board and audit committee actions, and financial-reporting controls.
The company's SEC disclosures also address accounting and reporting matters relevant to its Form 20-F status, including U.S. GAAP and SEC reporting requirements, independent registered public accounting firm appointments, and disclosed material weaknesses in internal control over financial reporting.
Baird Medical Investment Holdings Limited filed a post-effective amendment converting its Form F-1 into a Form F-3 and updated financials and disclosures. The amendment does not register additional securities and enables resale and future issuance under a shelf-style prospectus dated May 22, 2026. The prospectus registers up to 11,500,000 Ordinary Shares issuable upon exercise of warrants at $11.50 per share and up to 34,415,562 Ordinary Shares for resale by selling securityholders. The filing states the company will not receive proceeds from resale by selling securityholders and is unlikely to receive proceeds from warrant exercises at the May 21, 2026 closing price of $1.64 per share. The prospectus highlights China-related regulatory, cash‑transfer and HFCAA/PCAOB inspection risks and summarizes business focus, recent revenues and net income/(loss) for 2023–2025.
Baird Medical Investment Holdings Limited filed a Form F-3 shelf prospectus to offer up to US$50,000,000 of ordinary shares, preferred shares, debt securities, warrants and units, to be sold from time to time. The prospectus states offers may be at fixed, market or negotiated prices, through underwriters, agents or direct sales.
The company discloses revenue of $31.5M (2023), $37.0M (2024) and $22.5M (2025), net income of $10.7M (2023), $12.6M (2024) and a net loss of $27.5M (2025). Ordinary Shares outstanding were 42,208,763 and 290,000 Series A Preferred Shares issued. The prospectus highlights China-specific regulatory risks including HFCAA, CSRC filing requirements and cash-transfer restrictions.
Baird Medical Investment Holdings Ltd filing reports that Alta Partners LLC beneficially owns 1,995,604 shares of common stock, representing common stock issuable upon exercise of outstanding warrants. The position represents 5.1% of the class. The filing states the holdings were not acquired to change or influence control.
Baird Medical Investment Holdings Limited filed its annual Form 20-F as a Cayman Islands holding company whose operations are conducted through PRC subsidiaries. The report highlights that dividends and cash movements depend heavily on these subsidiaries and are subject to PRC foreign exchange and reserve restrictions.
The company details extensive PRC regulatory licensing for its Class III microwave ablation equipment and needles and a Class II biopsy needle, plus a Manufacture License for Class II and III medical devices valid to May 24, 2026. It discusses reliance on a concentrated distributor and customer base, third-party suppliers, and marketing service providers.
Key risks include evolving PRC healthcare regulation, the Holding Foreign Companies Accountable Act and possible Nasdaq delisting if PCAOB access is lost, prior compliance issues such as a lapsed manufacturing license and underpaid social insurance, dependence on tender processes and medical insurance reimbursement, and challenges in product development, clinical trials, and competition.
Baird Medical Investment Holdings Ltd director Xu Lijian filed an initial statement of beneficial ownership. The filing reports direct ownership of 25,000 RSU Shares (BDMD), indicating Xu’s equity position in the company through restricted stock unit shares.
Baird Medical Investment Holdings Ltd director Qiu Quan has filed an initial Form 3, formally registering as a reporting person for BDMD. The structured data shows no reported purchases, sales, or other transactions and no derivative positions in this initial ownership statement.
Baird Medical Investment Holdings Ltd submitted a Form 3 identifying Lu Rongjian as an officer of the company with the title Chief Technical Officer. The structured data shows no reported share transactions, derivative positions, or holding entries associated with this reporting person in this filing.
Baird Medical Investment Holdings Ltd director Gabrielle Bilciu-Wolfson has filed an initial Form 3 disclosing her stake in the company. She reports beneficial ownership of 20,000 shares of Baird Medical common stock, held directly, with no specific buy or sell transaction indicated in this filing.
Baird Medical Investment Holdings Ltd filed an initial insider ownership report for Li Jie Clara, who serves as Acting Chief Financial Officer. This Form 3 excerpt lists her as a reporting person but shows no reported transactions or derivative positions in the summarized data.
Baird Medical Investment Holdings Ltd director Ragan Joseph Douglas III filed an initial Form 3 reporting his holdings in the company. The filing shows direct ownership of 57,180 BDMD shares, establishing his starting equity position as a reporting insider, with no specific buy or sell transaction disclosed.